

# Hee Jeong Kim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4554660/publications.pdf>

Version: 2024-02-01

115  
papers

1,682  
citations

361413

20  
h-index

361022

35  
g-index

127  
all docs

127  
docs citations

127  
times ranked

2358  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nipple Areola Skin-Sparing Mastectomy With Immediate Transverse Rectus Abdominis Musculocutaneous Flap Reconstruction is an Oncologically Safe Procedure. <i>Annals of Surgery</i> , 2010, 251, 493-498.	4.2	98
2	Breast Cancer Statistics in Korea in 2017: Data from a Breast Cancer Registry. <i>Journal of Breast Cancer</i> , 2020, 23, 115.	1.9	94
3	Diagnostic accuracy and safety of $^{18}\text{F}$ -fluoro- $^{17}\beta$ -oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study. <i>Lancet Oncology</i> , 2019, 20, 546-555.	10.7	85
4	Vitamin D Deficiency is Correlated with Poor Outcomes in Patients with Luminal-type Breast Cancer. <i>Annals of Surgical Oncology</i> , 2011, 18, 1830-1836.	1.5	73
5	Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2021, 39, 3293-3305.	1.6	70
6	Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes. <i>Breast Cancer Research</i> , 2015, 17, 64.	5.0	66
7	Different prognostic significance of CD24 and CD44 expression in breast cancer according to hormone receptor status. <i>Breast</i> , 2011, 20, 78-85.	2.2	62
8	Breast Cancer Statistics in Korea, 2018. <i>Journal of Breast Cancer</i> , 2021, 24, 123.	1.9	58
9	Efficacy of Pectoral Nerve Block Type II for Breast-Conserving Surgery and Sentinel Lymph Node Biopsy: A Prospective Randomized Controlled Study. <i>Pain Research and Management</i> , 2018, 2018, 1-8.	1.8	55
10	Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 434-443.	1.6	52
11	Lymph node ratio and pN staging in patients with node-positive breast cancer: a report from the Korean breast cancer society. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 507-515.	2.5	46
12	A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 257-266.	2.5	41
13	A Randomized Feasibility Study of $^{18}\text{F}$ -Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptor-Rich Postmenopausal Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 563-568.	5.0	40
14	The impact of young age at diagnosis (age <40 years) on prognosis varies by breast cancer subtype: A U.S. SEER database analysis. <i>Breast</i> , 2022, 61, 77-83.	2.2	38
15	Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer. <i>British Journal of Cancer</i> , 2016, 114, 1109-1116.	6.4	37
16	Outcome following sentinel lymph node biopsy-guided decisions in breast cancer patients with conversion from positive to negative axillary lymph nodes after neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 473-480.	2.5	32
17	Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 54.	5.0	32
18	Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 499-505.	2.5	31

#	ARTICLE	IF	CITATIONS
19	Sentinel node biopsy in patients with multiple breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 109, 503-506.	2.5	28
20	A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor-Positive, Human Epidermal Growth Factor 2 (HER2)-Negative Breast Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 1073-1085.	3.0	23
21	Surgical Treatment After Neoadjuvant Systemic Therapy in Young Women With Breast Cancer. <i>Annals of Surgery</i> , 2022, 276, 173-179.	4.2	20
22	Functional Impairments in the Mental Health, Depression and Anxiety Related to the Viral Epidemic, and Disruption in Healthcare Service Utilization among Cancer Patients in the COVID-19 Pandemic Era. <i>Cancer Research and Treatment</i> , 2022, 54, 671-679.	3.0	19
23	Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer. <i>Breast Cancer</i> , 2016, 23, 771-779.	2.9	18
24	Survival of Breast-Conserving Surgery Plus Radiotherapy versus Total Mastectomy in Early Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 5039-5047.	1.5	18
25	Axillary Lymph Node Dissection Does Not Improve Post-mastectomy Overall or Disease-Free Survival among Breast Cancer Patients with 1-3 Positive Nodes. <i>Cancer Research and Treatment</i> , 2019, 51, 1011-1021.	3.0	18
26	Comparing Accuracy of Mammography and Magnetic Resonance Imaging for Residual Calcified Lesions in Breast Cancer Patients Undergoing Neoadjuvant Systemic Therapy. <i>Clinical Breast Cancer</i> , 2018, 18, e1087-e1091.	2.4	17
27	MRI-based 3D-printed surgical guides for breast cancer patients who received neoadjuvant chemotherapy. <i>Scientific Reports</i> , 2019, 9, 11991.	3.3	17
28	Oncologic Safety of Nipple-Sparing Mastectomy in Patients with Breast Cancer and Tumor-to-Nipple Distance $\leq 1$ cm: A Matched Cohort Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 4284-4291.	1.5	16
29	Claudin 1, 3, 4, and 7 expression in triple-negative breast cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 1070-1070.	1.6	16
30	Patient reporting pain intensity immediately after surgery can be associated with underlying depression in women with breast cancer. <i>Psycho-Oncology</i> , 2016, 25, 308-315.	2.3	15
31	Survival improvement in hormone-responsive young breast cancer patients with endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 311-320.	2.5	15
32	Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 657-665.	2.5	15
33	Targeted eicosanoids profiling reveals a prostaglandin reprogramming in breast Cancer by microRNA-155. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 43.	8.6	15
34	Interaction between body mass index and hormone-receptor status as a prognostic factor in lymph-node-positive breast cancer. <i>PLoS ONE</i> , 2017, 12, e0170311.	2.5	15
35	The Recurrence Rate, Risk Factors and Recurrence Patterns after Surgery in 3700 Patients with Operable Breast Cancer. <i>Journal of Breast Cancer</i> , 2006, 9, 134.	1.9	15
36	Concurrent Gonadotropin-Releasing Hormone Agonist Administration with Chemotherapy Improves Neoadjuvant Chemotherapy Responses in Young Premenopausal Breast Cancer Patients. <i>Journal of Breast Cancer</i> , 2015, 18, 365.	1.9	14

#	ARTICLE	IF	CITATIONS
37	Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: The ASTRRA study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 502-502.	1.6	14
38	Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 203-215.	2.5	13
39	Locoregional recurrence following nipple-sparing mastectomy with immediate breast reconstruction: Patterns and prognostic significance. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1309-1315.	1.0	13
40	No Association of Positive Superficial and/or Deep Margins with Local Recurrence in Invasive Breast Cancer Treated with Breast-Conserving Surgery. <i>Cancer Research and Treatment</i> , 2018, 50, 275-282.	3.0	13
41	Chronological Improvement in Survival of Patients with Breast Cancer: A Large-Scale, Single-Center Study. <i>Journal of Breast Cancer</i> , 2018, 21, 70.	1.9	12
42	Clinical Implication of HER2 Status in Hormone Receptor-Positive Mucinous Breast Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 2166-2174.	1.5	12
43	Pulmonary Thromboembolism following Mastectomy with Immediate TRAM in the Patients with Breast Cancer: a Prospective Study. <i>Journal of Breast Cancer</i> , 2006, 9, 354.	1.9	11
44	Survival Outcomes of Different Treatment Methods for the Ipsilateral Breast of Occult Breast Cancer Patients with Axillary Lymph Node Metastasis: A Single Center Experience. <i>Journal of Breast Cancer</i> , 2013, 16, 410.	1.9	11
45	Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients. <i>Scientific Reports</i> , 2020, 10, 17466.	3.3	11
46	Breast cancer diagnosis by analysis of serum N-glycans using MALDI-TOF mass spectroscopy. <i>PLoS ONE</i> , 2020, 15, e0231004.	2.5	11
47	Potential of MALDI-TOF-based serum N-glycan analysis for the diagnosis and surveillance of breast cancer. <i>Scientific Reports</i> , 2020, 10, 19136.	3.3	10
48	Breast-conserving surgery with 3D-printed surgical guide: a single-center, prospective clinical study. <i>Scientific Reports</i> , 2021, 11, 2252.	3.3	10
49	A Mobile Technology for Collecting Patient-Reported Physical Activity and Distress Outcomes: Cross-Sectional Cohort Study. <i>JMIR MHealth and UHealth</i> , 2020, 8, e17320.	3.7	10
50	A Propensity Score-matched Analysis of Long-term Oncologic Outcomes After Nipple-sparing Versus Conventional Mastectomy for Locally Advanced Breast Cancer. <i>Annals of Surgery</i> , 2020, Publish Ahead of Print, .	4.2	10
51	Adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: 8-year follow-up of the randomized ASTRRA trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 506-506.	1.6	10
52	Sentinel node biopsy alone for breast cancer patients with residual nodal disease after neoadjuvant chemotherapy. <i>Scientific Reports</i> , 2021, 11, 9056.	3.3	9
53	Risk of Endometrial Cancer and Frequencies of Invasive Endometrial Procedures in Young Breast Cancer Survivors Treated With Tamoxifen: A Nationwide Study. <i>Frontiers in Oncology</i> , 2021, 11, 636378.	2.8	9
54	A proposal for a new classification of T4 breast cancer as stage IIIc: a report from the Korean Breast Cancer Society. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 153-160.	2.5	8

#	ARTICLE	IF	CITATIONS
55	Long-term survival outcomes of repeat lumpectomy for ipsilateral breast tumor recurrence: a propensity score-matched analysis. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 155-164.	2.5	8
56	Usefulness of 3D-surgical guides in breast conserving surgery after neoadjuvant treatment. <i>Scientific Reports</i> , 2021, 11, 3376.	3.3	7
57	Result of Sentinel Lymph Node Biopsy Using Radioisotope in Clinically Lymph Node Negative Breast Cancer. <i>Journal of Breast Cancer</i> , 2007, 10, 141.	1.9	7
58	Plasma Proteome Signature to Predict the Outcome of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. <i>Cancers</i> , 2021, 13, 6267.	3.7	7
59	Mammographically occult breast cancers detected with AI-based diagnosis supporting software: clinical and histopathologic characteristics. <i>Insights Into Imaging</i> , 2022, 13, 57.	3.4	7
60	Characteristics and prognosis of breast cancer after liver or kidney transplantation. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 101-106.	2.5	6
61	The role of postoperative radiotherapy after primary tumor resection in patients with de novo stage IV breast cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 495-505.	1.1	6
62	Prognosis according to clinical and pathologic lymph node status in breast cancer patients who underwent sentinel lymph node biopsy alone after neoadjuvant therapy. <i>PLoS ONE</i> , 2021, 16, e0251597.	2.5	6
63	Primary Rhabdomyosarcoma of the Breast: Study of Three Cases at One Institution with a Review of Primary Breast Sarcomas. <i>Journal of Pathology and Translational Medicine</i> , 2019, 53, 308-316.	1.1	6
64	Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node-Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer. <i>Cancer Research and Treatment</i> , 2016, 48, 1351-1362.	3.0	6
65	A nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer. <i>Scientific Reports</i> , 2021, 11, 23509.	3.3	6
66	Risk stratification system for groups with a low, intermediate, and high risk of subsequent distant metastasis and death following isolated locoregional recurrence of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 315-324.	2.5	5
67	The effects of poloxamer and sodium alginate mixture (Guardix-SG <sup>®</sup> ) on range of motion after axillary lymph node dissection: A single-center, prospective, randomized, double-blind pilot study. <i>PLoS ONE</i> , 2020, 15, e0238284.	2.5	5
68	Association between Oncotype DX recurrence score and dynamic contrast-enhanced MRI features in patients with estrogen receptor-positive HER2-negative invasive breast cancer. <i>Clinical Imaging</i> , 2021, 75, 131-137.	1.5	5
69	A propensity score-matched comparison of recurrence outcomes after immediate implant vs autologous flap reconstruction in patients receiving neoadjuvant chemotherapy for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 417-425.	2.5	4
70	The Impact of Androgen Receptor and Histone Deacetylase 1 Expression on the Prognosis of Ductal Carcinoma <i>in Situ</i> . <i>Journal of Breast Cancer</i> , 2020, 23, 610.	1.9	4
71	The Importance of Education regarding the Effects of Anticancer Treatment on Fertility and Ovarian Function in the Female Patients with Breast Cancer. <i>Journal of Menopausal Medicine</i> , 2019, 25, 142.	1.1	4
72	Oncologic outcomes of immediate breast reconstruction in young women with breast cancer receiving neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 345-354.	2.5	4

#	ARTICLE	IF	CITATIONS
73	Relationship of Bone mineral density and the risk of breast cancer in Korean postmenopausal women. <i>Journal of Breast Cancer</i> , 2006, 9, 330.	1.9	3
74	Survival analysis according to period and analysis of the factors influencing changes in survival in patients with recurrent breast cancer: a large-scale, single-center study. <i>Breast Cancer</i> , 2018, 25, 639-649.	2.9	3
75	Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer with axillary node metastasis: A survey of clinical practice. <i>Asian Journal of Surgery</i> , 2019, 42, 314-319.	0.4	3
76	Prediction of Late Breast Cancer-Specific Mortality in Recurrence-Free Breast Cancer Survivors Treated for Five Years with Tamoxifen. <i>Journal of Breast Cancer</i> , 2019, 22, 387.	1.9	3
77	Survival outcome of adjuvant endocrine therapy alone for patients with lymph node-positive, hormone-responsive, HER2-negative breast cancer. <i>Asian Journal of Surgery</i> , 2019, 42, 914-921.	0.4	3
78	Changes in bone mineral density during 5 years of adjuvant treatment in premenopausal breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 657-663.	2.5	3
79	Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer. <i>Scientific Reports</i> , 2021, 11, 10510.	3.3	3
80	Breast cancer outcomes following immediate breast reconstruction with implants versus autologous flaps: a propensity score-matched study. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 365-373.	2.5	3
81	Clinicopathological characteristics and outcomes of malignant adenomyoepithelioma of the breast: a single institution's experience. <i>World Journal of Surgical Oncology</i> , 2022, 20, 128.	1.9	3
82	Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1117-1126.	6.3	3
83	Association between tumor 18F-fluorodeoxyglucose metabolism and survival in women with estrogen receptor-positive, HER2-negative breast cancer. <i>Scientific Reports</i> , 2022, 12, 7858.	3.3	3
84	Comparison of survival outcomes for axillary surgery extent based on intraoperative sentinel lymph node biopsy result after neoadjuvant chemotherapy for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 647-655.	2.5	2
85	Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 741120.	2.8	2
86	Neutrophil lymphocyte ratio (NLR) change after systemic treatment as a predictive factor of cancer specific survival in stage IV breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 29-29.	1.6	2
87	Change in Estradiol Levels among Premenopausal Patients with Breast Cancer Treated Using Leuprolide Acetate 11.25 Milligrams 3-Month Depot and Tamoxifen. <i>Journal of Breast Cancer</i> , 2020, 23, 553.	1.9	2
88	Association of mammography and ultrasound features with MammaPrint in patients with estrogen receptor-positive, HER2-negative, node-positive invasive breast cancer. <i>Acta Radiologica</i> , 2021, 62, 1592-1600.	1.1	2
89	Improvement of survival in Korean breast cancer patients over a 14-year period: A large-scale single-center study. <i>PLoS ONE</i> , 2022, 17, e0265533.	2.5	2
90	Oncologic Safety of Gonadotropin-Releasing Hormone Agonist for Ovarian Function Protection During Breast Cancer Chemotherapy. <i>Clinical Breast Cancer</i> , 2018, 18, e1165-e1172.	2.4	1

#	ARTICLE	IF	CITATIONS
91	Is asymptomatic surveillance beneficial after standard treatment? A 10-year survival analysis of recurrent BC patients by detection method of recurrence. <i>Breast Journal</i> , 2020, 26, 556-559.	1.0	1
92	Prognostic value of p53 expression in hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients receiving neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 447-454.	2.5	1
93	Factors Predicting Locoregional Recurrence After Neoadjuvant Chemotherapy and Nipple-Sparing/Skin-Sparing Mastectomy With Immediate Breast Reconstruction. <i>Frontiers in Oncology</i> , 2021, 11, 675955.	2.8	1
94	Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 608207.	2.8	1
95	A phase III, open label, prospective, randomized, multicenter, neoadjuvant study of chemotherapy versus endocrine therapy in premenopausal patient with hormone responsive, HER2 negative, breast cancer (KBCSG 012).. <i>Journal of Clinical Oncology</i> , 2017, 35, 517-517.	1.6	1
96	Primary Rhabdomyosarcoma of the Breast: A Report of Two Cases and Literature Review. <i>Journal of Pathology and Translational Medicine</i> , 2018, , .	1.1	1
97	Surgical Treatment of Locoregional Recurrence in Breast Cancer. <i>Journal of Breast Cancer</i> , 2006, 9, 241.	1.9	1
98	Comparison of Early Postoperative Axillary Morbidity Following the Sentinel Lymph Node Biopsy or Axillary Lymph Node Dissection. <i>Journal of Breast Cancer</i> , 2007, 10, 107.	1.9	1
99	Chemotherapy for ipsilateral breast tumor recurrence: a propensity score-matching study. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 143-152.	2.5	1
100	Abstract P2-13-42: Effect of young age at diagnosis on clinical outcomes and efficacy of anti-HER2 targeted therapy in patients with HER2-positive early breast cancer: Results from the APHINITY trial. <i>Cancer Research</i> , 2022, 82, P2-13-42-P2-13-42.	0.9	1
101	The Association of Estrogen Receptor Activity, Interferon Signaling, and MHC Class I Expression in Breast Cancer. <i>Cancer Research and Treatment</i> , 2022, 54, 1111-1120.	3.0	1
102	Clinical Course and Predictors of Subsequent Recurrence and Survival of Patients With Ipsilateral Breast Tumor Recurrence. <i>Cancer Control</i> , 2022, 29, 107327482210894.	1.8	1
103	Experience of Ovarian Function Suppression Therapy: Endocrine Response Preand Perimenopausal Korean Breast Cancer Patients in the Adjuvant Setting. <i>Journal of Breast Cancer</i> , 2007, 10, 134.	1.9	0
104	Data on distant metastasis and survival after locoregional recurrence following nipple-sparing mastectomy and immediate breast reconstruction. <i>Data in Brief</i> , 2021, 35, 106837.	1.0	0
105	Impact of Local Breast Cancer Recurrence on Reconstructed Breast in Nipple-Sparing Mastectomy with Immediate Reconstruction. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2021, , .	1.0	0
106	Predictive factors of no response during neoadjuvant chemotherapy in breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, e11508-e11508.	1.6	0
107	Stage, biology, and age.. <i>Journal of Clinical Oncology</i> , 2013, 31, e11512-e11512.	1.6	0
108	Approach to Serial Liquid Biopsy: Enrichment of circulating tumor cells (CTC) in breast cancer patients for cancer panel analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, e22029-e22029.	1.6	0



#	ARTICLE	IF	CITATIONS
109	A proposal for a new classification of T4 breast cancer as stage IIIC.. Journal of Clinical Oncology, 2015, 33, e11585-e11585.	1.6	0
110	Prognosis of breast cancer as a result of late recurrence in hormone receptor-positive tumor.. Journal of Clinical Oncology, 2015, 33, e11587-e11587.	1.6	0
111	A survey investigating the current situation of the international visiting scholar program at the department of surgery in Korea. Annals of Surgical Treatment and Research, 2020, 99, 189.	1.0	0
112	Abstract P4-09-03: Factors affecting the parenting stress and depression in young women with breast cancer. Cancer Research, 2022, 82, P4-09-03-P4-09-03.	0.9	0
113	Abstract P4-10-18: The effects of preoperative personalized music therapy associated with the patient-doctor relationship and surgical experience of patients with breast cancer (MARS). Cancer Research, 2022, 82, P4-10-18-P4-10-18.	0.9	0
114	Is There a Difference in the Diagnosis and Prognosis of Local Recurrence between Autologous Tissue and Implant-Based Breast Reconstruction?. Breast Journal, 2022, 2022, 1-8.	1.0	0
115	Breast density reduction as a predictor for prognosis in premenopausal women with hormone receptor-positive breast cancer: A retrospective analysis of the ASTRRA study.. Journal of Clinical Oncology, 2022, 40, 531-531.	1.6	0